Bausch Health Q4 Revenue Rises 9.3% to $2.8B, EPS Misses by 10.5%
Bausch Health posted Q4 revenue of $2.8 billion, up 9.3% year-over-year and 3.4% above estimates, while adjusted EPS fell to $1.08, missing consensus by 10.5%. All major segments, led by a 16% jump in Pharmaceuticals and 11.8% gain in Diversified Products, showed positive sales growth.
1. Q4 Financial Results
Bausch Health reported Q4 revenue of $2.8 billion, up 9.3% year-over-year and 3.4% above consensus, while adjusted EPS of $1.08 fell 10.5% short of estimates and declined from $1.15 a year ago.
2. Segment Revenue Performance
Bausch + Lomb revenues rose 9.8% to $1.41 billion, Diversified Products increased 11.8% to $255 million, Vision Care grew 7.6% to $778 million, Surgical sales climbed 7.8% to $249 million, and Pharmaceuticals surged 16% to $378 million; Solta Medical slipped 0.7% to $137 million.
3. Outlook and Market Reaction
The company projects 2026 revenue between $10.63 billion and $10.88 billion, while the stock has declined 11.8% over the past month. Analysts maintain a neutral stance, reflecting mixed earnings surprises and segment performances.